Sorbent Therapeutics Inc. closed a $53 million Series B financing round led by new investor Novartis Venture Funds.
A Bay Area transplant from Chicago, the three-employee Sunnyvale company will use the money to complete a mid-stage program for its lead congestive heart failure drug and slowly add a few employees, CEO Detlef Albrecht said.
No comments:
Post a Comment